The overlap Between binge eating disorder and substance use disorders: Diagnosis and neurobiology

Journal of Behavioral Addictions

Volumn 2, Issue 4, 2013, Pages 191-198

  Schreiber, Liana R N ^a   Odlaug, Brian L ^b   Grant, Jon E ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Addiction; Binge eating disorder; Comorbidity; Substance use disorder

Indexed keywords

EID: 84923221534     PISSN: 20625871     EISSN: 20635303     Source Type: Journal    
DOI: 10.1556/JBA.2.2013.015     Document Type: Article

References (79)

1. Ait-Daoud, N., Roache, J. D., Dawes, M. A., Liu, L., Wang, X-Q., Javors, M. A., Seneviratne, C. & Johnson, B. A. (2009). Can serotonin transporter genotype predict craving in alcoholism? Alcohol Clinical Experimental Research, 33 (8), 1329-1335.
2. Alger, S. A., Schwalberg, M. D., Bigaouette, J. M., Michalek, A. V. & Howard, L. J. (1991). Effect of a tricyclic antidepressant and opiate antagonist on binge-eating behavior in normoweight bulimic and obese, binge-eating subjects. The American Journal of Clinical Nutrition, 53 (4), 865-871.
3. th ed.). Arlington, VA: Author.
4. Anderson, J. W., Greenway, F. L., Fuijoka, K., Gadde, K. M., McKenney, J. & O'Neil, P. M. (2002). Bupropion SR enhances weight loss: A 28-week double-blind, placebo-controlled trial. Obesity Research, 10 (7), 633-641.
5. Arbaizar, B., Dierssen-Sotos, T., Gómez-Acebo, I. & Llorca J. (2010). Topiramate in the treatment of alcohol dependence: A meta-analysis. Actas Españolas de Psiquiatría, 38, 8-12.
6. Asin, K. E., Davis, J. D. & Bednarz, L. (1992). Differential effects of serotonergic and catecholaminergic drugs on ingestive behavior. Psychopharmocology (Berlin), 109, 415-421.
7. Avena, N. M., Rada, P. & Hoebel, B. G. (2008). Evidence for sugar addiction: Behavioral and neurochemical effects of intermittent, excessive sugar intake. Neuroscience Biobehavioral Review, 31, 20-39.
8. Avena, N. M., Rada, P. & Hoebel, B. G. (2009). Sugar and fat binging have notable differences in addictive-like behavior. The Journal of Nutrition, 139 (3), 623-628.
9. Baker, D. A., McFarland, K., Lake, R. W., Shen, H., Tang, X. C., Toda, S. & Kalivas, P. W. (2003). Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nature Neuroscience, 6, 743-749.
10. Balodis, I. M., Molina, N. D., Kober, H., Worhunsky, P. D., White, M. A., Sinha, R., Grilo, C. M. & Potenza, M. N. (2013). Divergent neural substrates of inhibitory control in binge eating disorder relative to other manifestations of obesity. Obesity, 21(2), 367-377.
11. Brody, A. L., Mandelkern, M. A., Lee, G., Smith, E., Sadeghi, M., Saxena, S., Jarvik, M. E. & London, E. D. (2004). Attenuation of cue-included cigarette craving and anterior cingulate cortex activation in bupropion treated smokers: A preliminary study. Psychiatry Research, 130, 269-281.
12. Bulik, C. M., Sullivan, P. F. & Kendler, K. S. (2002). Medical and psychiatric morbidity in obese women with and without binge eating. The International Journal of Eating Disorders, 32(1), 72-78.
13. Cambridge, V. C., Ziauddeen, H., Nathan, P. J., Subramaniam, N., Dodds, C., Chamberlain, S. R., Koch, A., Maltby, K., Skeggs, A. L., Napolitano, A., Farooqi, I. S., Bullmore, E. T. &Fletcher, P. C. (2013). Neural and behavioral effects of a novel mu opioid receptor antagonist in binge-eating obese people. Biological Psychiatry, 73, 887-894.
14. Cassin, S. E. & von Ranson, K. M. (2007). Is binge eating experienced as an addiction? Appetite, 49 (3), 687-690.
15. Chamberlain, S. R., Mogg, K., Bradley, B. P., Koch, A., Dodds, C. M., Tao, W. X., Maltby, K., Sarai, B., Napolitano, A., Richards, D. B., Bullmore, E. T. & Nathan, P. J. (2012). Effects of mu opioid receptor antagonism on cognition in obese binge-eating individuals. Psychopharmacology (Berlin), 224(4), 501-509.
16. Claudino, A. M., de Oliveira, I. R., Appolinario, J. C., Cordás, T. A., Duchesne, M., Sichieri, R. & Bacaltchuk, J. (2007). Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive behavioral therapy in binge eating disorder. The Journal of Clinical Psychiatry, 68, 1324-1332.
17. Corsica, J. A. & Spring, B. J. (2008). Carbohydrate craving: A double-blind, placebo-controlled test of the self-medication hypothesis. Eating Behaviors, 9, 447-454.
18. Cottone, P., Sabino, V., Steardo, L. & Zorrilla, E. P. (2008). Opioid-dependent anticipatory negative contrast and binge-like eating in rats with limited access to highly preferred food. Neuropsychopharmacology, 33, 524-535.
19. Davis, C. & Carter, J. C. (2009). Compulsive overeating as an addiction disorder: A review of theory and evidence. Appetite, 53, 1-8.
20. Davis, C., Curtis, C., Levitan, R. D., Carter, J. C., Kaplan, A. S. &Kennedy, J. L. (2011). Evidence that 'food addiction' is a valid phenotype of obesity. Appetite, 57, 711-717.
21. Davis, C. A., Levitan, R. D., Reid, C., Carter, J. C., Kaplan, A. S., Patte, K. A., King, N., Curtis, C. & Kennedy, J. L. (2009). Dopamine for "wanting" and opioids for "liking": A comparison of obese adults with and without binge eating. Obesity, 17, 1220-1225.
22. Dingemans, A. E., Bruna, M. J. & van Furth, E. F. (2002). Binge eating disorder: A review. The Journal of Obesity Related Metabolism Disorders, 26, 299-307.
23. Drewnowski, A., Krahn, D. D., Demitrack, M. A., Nairn, K. &Gosnell, B. A. (1995). Naloxone, an opiate blocker, reduces the consumption of sweet high-fat foods in obese and lean female binge eaters. The American Journal of Clinical Nutrition, 61, 1206-1212.
24. Ferriter, C. & Ray, L. A. (2011). Binge eating and binge drinking: An integrative review. Eating Behaviors, 12, 99-107.
25. Fortuna, J. L. (2012). The obesity epidemic and food addition: Clinical similarities to drug dependence. Journal of Psychoactive Drugs, 44(1), 56-63.
26. Gadalla, T. & Piran, N. (2007). Co-occurrence of eating disorders and alcohol use disorders in women: A meta analysis. Archives of Women's Mental Health, 10, 133-140.
27. Gadde, K. M., Parker, C. B., Maner, L. G., Wagner, H. R., 2nd, Logue, E. J., Drezner, M. K. & Krishnan, K. R. (2001). Bupropion for weight loss: An investigation of efficacy and tolerability in overweight and obese women. Obesity Research, 9 (9), 544-551.
28. Garbutt, J. C., West, S. L., Carey, T. S., Lohr, K. N. & Crews, F. T. (1999). Pharmacological treatment of alcohol dependence. The Journal of American Medical Association, 281, 1318-1325.
29. Gearhardt, A. N., Corbin, W. R. & Brownell, K. D. (2009). Preliminary validation of the Yale Food Addiction Scale. Appetite, 62, 430-436.
30. Gearhardt, A. N., White, M. A. & Potenza, M. N. (2011). Binge eating disorder and food addiction. Current Drug Abuse Review, 4, 201-207.
31. Grant, J. E., Potenza, M. N., Weinstein, A. & Gorelick, D. A. (2010). Introduction to behavioral addictions. The American Journal of Drug and Alcohol Abuse, 36, 233-241.
32. Greenway, F. L., Dunayevich, E., Tollefson, G., Erickson, J., Guttadauria, M., Fujioka, K. & Cowley, M. A. (2009). Comparison of combined bupropion and naltrexone therapy for obesity with monotherpay and placebo. The Journal of Clinical Endocrinology and Metabolism, 94 (12), 4898-4906.
33. Grilo, C. M., White, M. A. & Masheb, R. M. (2009). DSM-IV psychiatric disorder comorbidity and its correlates in binge eating disorder. The International Journal of Eating Disorders, 42, 228-234.
34. Haltia, L. T., Rinne, J. O., Merisaari, H., Maguire, R. P., Savontaus, E., Helin, S., Någren, K. & Kaasinen, V. (2007). Effects of intravenous glucose on dopaminergic function in the human brain in vivo. Synapse, 61(9), 748-756.
35. Hommer, R. E., Seo, D., Lacadie, C. M., Chaplin, T. M., Mayes, L. C., Sinha, R. & Potenza, M. N. (2012). Neural correlates of stress and favorite-food cue exposure in adolescents: A functional magnetic resonance imaging study. Human Brain Mapping, Epub ahead of print, doi: 10.1002/hbm.22089.
36. Hudson, J. I., McElroy, S. L., Raymond, N. C., Crow, S., Keck, P. E., Jr., Carter, W. P., Mitchell, J. E., Strakowski, S. M., Pope, H. G., Jr., Coleman, B. S. & Jonas, J. M. (1998). Fluvoxamine in the treatment of binge-eating disorder: A multicenter pla-cebo- controlled trial. The American Journal of Psychiatry, 155, 1756-1762.
37. Ifland, J. R., Preuss, H. G., Marcus, M. T., Rourke, K. M., Taylor, W. C., Burau, K., Jacobs, W. S., Kadish, W. & Manso, G. (2009). Refined food addiction: A classic substance use disorder. Medical Hypotheses, 72, 518-526.
38. Jain, A. K., Kaplan, R. A., Gadde, K. M., Wadden, T. A., Allison, D. B., Brewer, E. R., Leadbetter, R. A., Richard, N., Haight, B., Jamerson, B. D., Buaron, K. S. & Metz, A. (2002). Bupropion SR vs placebo for weight loss in obese patients with depressive symptoms. Obesity Research, 10, 1049-1056.
39. Johnson, P. M. & Kenny, P. J. (2010). Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats. Nature Neuroscience, 13, 635-641.
40. Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., Fiore, M. C. & Baker, T. B. (1999). A controlled trial of sustained released bupropion, a nicotine patch, or both for smoking cessation. The New England Journal of Medicine, 340, 685-691.
41. Kessler, R. C., Berglund, P. A., Chiu, W. T., Deitz, A. C., Hudson, J. I., Shahly, V., Aguilar-Gaxiola, S., Alonso, J., Angermeyer, M. C., Benjet, C., Bruffaerts, R., de Girolamo, G., de Graaf, R., Maria Haro, J., Kovess-Masfety, V., O'Neill, S., Posada-Villa, J., Sasu, C., Scott, K., Viana, M. C. & Xavier, M. (2013). The prevalence and correlates of binge eating disorder in the World Health Organization World Mental Health Surveys. Biological Psychiatry, 73, 904-914.
42. King, A. C., Cao, D., Zhang, L. & O'Malley, S. S. (2013). Naltrexone reduction of long-term smoking cessation weight gain in women but not men: A randomized controlled trial. Biological Psychiatry, 73, 924-930.
43. Koob, G. F. & Le Moal, M. (2001). Drug addiction, dysregulation of reward, and allostatis. Neuropsychopharmacology, 24, 97-129.
44. Lewinsohn, P. M., Seeley, J. R., Moerk, K. C. & Striegel-Moore, R. H. (2002). Gender differences in eating disorder symptoms in young adults. International Journal of Eating Disorders, 32, 426-440.
45. Lilenfeld, L. R. R., Ringham, R., Kalarchian, M. A. & Marcus, M. D. (2008). A family history study of binge-eating disorder. Comprehensive Psychiatry, 49, 247-254.
46. Luce, K. H., Engler, P. A. & Crowther, J. H. (2007). Eating disorders and alcohol use: Group differences in consumption rates and drinking motives. Eating Behaviors, 8, 177-184.
47. Maldonado-Irizarry, C. S., Swanson, C. J. & Kelley, A. E. (1995). Glutamate receptors in the nucleus accumbens shell control feeding behavior via the lateral hypothalamus. The Journal of Neuroscience, 15, 6779-6788.
48. Marrazzi, M. A., Markham, K. M., Kinzie, J. & Luby, E. D. (1995). Binge eating disorder: Response to naltrexone. The International Journal of Obesity and Related Metabolism Disorders, 19(2), 143-145.
49. McElroy, S. L., Arnold, L. M., Shapira, N. A., Keck, P. E., Jr., Rosenthal, N. R., Karim, M. R., Kamin, M. & Hudson, J. I. (2003). Topiramate in the treatment of binge eating disorder associated with obesity: A randomized, placebo-controlled trial. The American Journal of Psychiatry, 160, 255-261.
50. McElroy, S. L., Casuto, L. S., Nelson, E. B., Lake, K. A., Soutullo, C. A., Keck, P. E., Jr. & Hudson, J. I. (2000). Placebo-controlled trial of sertraline in the treatment of binge eating disorder. The American Journal of Psychiatry, 157, 1004-1006.
51. McElroy, S. L., Guerdjikova, A. I., Mori, N. & O'Melia, A. M. (2012). Pharmacological management of binge eating disorder: Current and emerging treatment options. Therapeutics and Clinical Risk Management, 8, 219-241.
52. McElroy, S. L., Guerdjikova, A. I., Winstanley, E. L., O'Melia, A. M., Mori, N., McCoy, J., Keck, P. E. & Hudson, J. I. (2011). Acamprosate in the treatment of binge eating disorder: A placebo-controlled trial. The International Journal of Eating Disorders, 44, 81-90.
53. McElroy, S. L., Hudson, J. I., Capece, J. A., Beyers, K., Fisher, A. C., Rosenthal, N. R. & Topiramate Binge Eating Disorder Research Group. (2007). Topiramate for the treatment of binge eating disorder associated with obesity: A placebo-controlled study. Biological Psychiatry, 61, 1039-1048.
54. Merikangas, K. R. & McClair, V. L. (2012). Epidemiology of substance use disorder. Human Genetics, 131, 779-789.
55. Meyer, F. (2008). Alleviation of both binge eating and sexual dysfunction with naltrexone. The Journal of Clinical Psychopharmacology, 28 (6), 722-723.
56. Miller, P. M., Book, S. W. & Stewart, S. H. (2011). Medical treatment of alcohol dependence: A systematic review. The International Journal of Psychiatry Medicine, 42 (3), 227-266.
57. Myers, K. M., Carlezon, W. A., Jr. & Davis, M. (2011). Glutamate receptors in extinction and extinction-based therapies for psychiatric illness. Neuropsychopharmacology, 36, 274-293.
58. Neumeister, A., Winkler, A. & Wober-Bingol, C. (1999). Addition of naltrexone to fluoxetine in the treatment of binge eating disorder. The American Journal of Psychiatry, 156 (5), 797.
59. Rabiner, E. A., Beaver, J., Makwana, A., Searle, G., Long C., Nathan, P. J., Newbould, R. D., Howard, J., Miller, S. R., Bush, M. A., Hill, S., Reiley, R., Passchier, J., Gunn, R. N., Matthews, P. M. & Bullmore, E. T. (2011). Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans. Molecular Psychiatry, 16, 826-835.
60. Schaechter, J. D. & Wurtman, R. J. (1990). Serotonin release varies with brain tryptophan levels. Brain Research, 532, 203-210.
61. Sheng, L. X., Tang, Y. L., Jiang, Z. N., Yao, C. H., Gao, J. Y., Xu, G. Z. & Tong, X. Y. (2013). Sustained-release bupropion for smoking cessation in Chinese sample: A double-blind, placebo-controlled, randomized trial. Nicotine & Tobacco Research, 15(2), 320-325.
62. Sim, L. A., McAlpine, D. E., Grothe, K. B., Himes, S. M., Cockerill, R. G. & Clark, M. M. (2010). Identification and treatment of eating disorders in the primary care setting. Mayo Clinic Proceedings, 85, 746-751.
63. Smith, D. G. & Robbins, T. W. (2013). The neurobiological underpinnings of obesity and binge eating: A rationale for adopting the food addiction model. Biological Psychiatry, 72(9), 804-810.
64. Snyder, J. L. & Bowers, T. G. (2008). The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: A relative benefits analysis of randomized controlled trials. The American Journal of Drug and Alcohol Abuse, 34, 449-461.
65. Spring, B., Wurtman, J., Gleason, R. & Kessler, K. (1991). Weight gain and withdrawal symptoms after smoking cessation: A preventive intervention using d-fenfluramine. Health Psychology, 10, 216-223.
66. Tanofsky-Kraff, M., Bulik, C. M., Marcus, M. D., Striegel, R. H., Wilfley, D. E., Wonderlich, S. A.&Hudson, J. I. (2013). Binge eating disorder: The next generation of research. The International Journal of Eating Disorders, 46, 193-207.
67. Tata, A. L. & Kockler, D. R. (2006). Topiramate for binge-eating disorder associated with obesity. The Annals of Pharmacotherapy, 40(11), 1993-1997.
68. Thanos, P. K., Bermeo, C., Wang G. J. & Volkow, N. D. (2011). Bromocriptine increased operant responding for high fat food but decreased chow intake in both obesity-prone and resistant rats. Behavioural Brain Research, 217, 165-170.
69. van den Brink, W. (2012). Evidence-based pharmacological treatment of substance use disorder and pathological gambling. Current Drug Abuse Review, 5, 3-31.
70. Volkow, N. D., Wang, G. J., Telang, F., Fowler, J. S., Thanos, P. K., Logan, J., Alexoff, D., Ding, Y. S., Wong, C., Ma, Y. &Pradhan, K. (2008). Low dopamine striatal D2 receptors are associated with prefrontal metabolism in obese subjects: Possible contributing factors. Neuroimage, 42 (4), 1537-1543.
71. Volkow, N. D., Wang, G. J., Tomasi, D. & Baler, R. D. (2013). Obesity and addiction: Neurobiological overlaps. Obesity Review, 14, 2-18.
72. Wang, G. J., Geliebter, A., Volkow, N. D., Telang, F. W., Logan, J., Jayne, M. C., Galanti, K., Selig, P. A., Han, H., Zhu, W., Wong, C. T. & Fowler, J. S. (2011). Enhanced striatal dopamine released during food stimulation in binge eating disorder. Obesity, 19, 1601-1608.
73. Wang, G. J., Volkow, N. D., Logan, J., Pappas, N. R., Wong, C. T., Zhu, W., Netusil, N. & Fowler, J. S. (2001). Brain dopamine and obesity. Lancet, 357, 354-357.
74. Wang, G. J., Volkow, N. D., Thanos, P. K. & Fowler, J. S. (2004). Similarity between obesity and drug addiction as assessed by neurofunctional imagining: A concept review. Journal of Addictive Disorders, 23, 39-53.
75. White, M. A. & Grilo, C. M. (2013). Bupropion for overweight women with binge-eating disorder: A randomized, dou-ble- blind, placebo-controlled trial. Journal of Clinical Psychiatry, 74(4), 400-406.
76. Wise, R. A. (2004). Rewards wanted: Molecular mechanisms of motivation. Discovery Medicine, 4, 180-186.
77. Zhang, M., Gosnell, B. A. & Kelley, A. E. (1998). Intake of high-fat food is selectively enhanced by mu opioid receptor stimulation within the nucleus accumbens. The Journal of Pharmacology and Experimental Therapeutics, 285, 908-914.
78. Ziauddeen, H., Farooqi, I. S. & Fletcher, P. C. (2012). Obesity and the brain: How convincing is the addiction model. Nature Reviews Neuroscience, 13, 279-286.
79. Ziauddeen, H. & Fletcher, P. C. (2012). Is food addiction a valid and useful concept? Obesity Reviews, 14, 19-28.